Bailard’s Agios Pharmaceuticals AGIO Stock Holding History

Bailard’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,600	Closed	-$309K	–	701
2021 Q2	$309K	Buy	+5,600	New	+$313K	0.01%	513

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Bailard's AGIO Position: Q3 2021 in Review

Bailard sold out of Agios Pharmaceuticals (AGIO) in Q3 2021, closing a stake of 5,600 shares — an estimated $309K sold.

Bailard first reported a position in AGIO in Q2 2021 and held it in 1 quarter. The position peaked at $309K in Q2 2021. 164 funds tracked by Wall St. Rank hold AGIO as of Q3 2021.

Bailard reported no remaining Agios Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Bailard sold 5,600 Agios Pharmaceuticals shares in Q3 2021, an estimated $309K.
Bailard first reported a position in Agios Pharmaceuticals in Q2 2021 and held it in 1 quarter.
Bailard's Agios Pharmaceuticals position peaked at $309K in Q2 2021.
164 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2021.

Based on Bailard's 13F filing for Q3 2021, filed 15 Nov 2021.